# Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

> **NCT04375800** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 84 (estimated)

## Conditions studied

- Human Immunodeficiency Virus (HIV) Infection

## Interventions

- **DRUG:** Doravirine
- **DRUG:** 2 NRTIs
- **DRUG:** DOR/3TC/TDF

## Key facts

- **NCT ID:** NCT04375800
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-03
- **Primary completion:** 2028-11-12
- **Final completion:** 2034-04-11
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04375800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04375800, "Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04375800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*